The aim of this study was to investigate the cardiovascular effects of SGLT2 inhibition in patients undergoing cardiac surgery, as HF is a clinically relevant concern both pre‐ and postoperatively, and optimizing treatment with SGLT2 inhibitors could improve patient outcomes [9, 10]. The gene discussed is SLC5A2; the disease is hydrops fetalis.